Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) Equity Ratio (2016 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Equity Ratio for 16 consecutive years, with 0.86 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Ratio rose 1.14% year-over-year to 0.86, compared with a TTM value of 0.86 through Dec 2025, up 1.14%, and an annual FY2025 reading of 0.86, up 1.14% over the prior year.
  • Equity Ratio was 0.86 for Q4 2025 at Catalyst Pharmaceuticals, down from 0.88 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.9 in Q2 2021 and bottomed at 0.8 in Q4 2022.
  • Average Equity Ratio over 5 years is 0.86, with a median of 0.86 recorded in 2024.
  • The sharpest move saw Equity Ratio increased 6.77% in 2021, then decreased 8.05% in 2022.
  • Year by year, Equity Ratio stood at 0.87 in 2021, then fell by 8.05% to 0.8 in 2022, then rose by 3.16% to 0.83 in 2023, then grew by 3.58% to 0.85 in 2024, then rose by 1.14% to 0.86 in 2025.
  • Business Quant data shows Equity Ratio for CPRX at 0.86 in Q4 2025, 0.88 in Q3 2025, and 0.88 in Q2 2025.